Using model-system genetics for drug-based target discovery.
Explore this paper's citation graph
Summary
The combination of medicinal chemistry and model-organism genetics is emerging as a powerful tool for the discovery and validation of drug targets, and the availability of human genomic sequence data is opening up new opportunities for accelerating target discovery.
- Type
- article
- Published
- 2001-02-01
- Cited by
- 27
- References
- 52
- OpenAlex
- https://openalex.org/W2013003323
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:37764261
Keywords
Drug discovery, Computational biology, Model organism, Organism, Biology
References
- Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans
- A single-amino acid substitution in a gamma-aminobutyric acid subtype A receptor locus is associated with cyclodiene insecticide resistance in Drosophila populations.
- Peptide Sequencing by Mass Spectrometry for Homology Searches and Cloning of Genes
- GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha.
- Genetic and pharmacological analysis of neurotransmitters controlling egg laying in C. elegans
- Gene expression analysis by transcript profiling coupled to a gene database query
- Knowledge-based analysis of microarray gene expression data by using support vector machines.
- Genetic pharmacology: interactions between drugs and gene products in Caenorhabditis elegans.
- The regulation of acetyl-CoA carboxylase--a potential target for the action of hypolipidemic agents.
- Analysis of large-scale gene expression data.
- Serotonin inhibition of synaptic transmission: Galpha(0) decreases the abundance of UNC-13 at release sites.
- Requirement of circadian genes for cocaine sensitization in Drosophila.
- A Single Point Mutation in CTP Synthetase of Chlamydia trachomatis Confers Resistance to Cyclopentenyl Cytosine*
- Drug discovery: a historical perspective.
- Fluoxetine-resistant mutants in C. elegans define a novel family of transmembrane proteins.
- Total synthesis of (+)-phorboxazole A.
- The identification of myriocin-binding proteins.
- Inhibition of Angiogenesis In Vivo by ets-1 Antisense Oligonucleotides-Inhibition of Ets-1 Transcription Factor Expression by the Antibiotic Fumagillin.
- Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice.
- Genetics of RAS signaling in C. elegans.
Cited by
- METODOLOGIA PARA QUANTIFICAR RICINA EM SEMENTES DE MAMONA COM O USO DE Caenorhabditis elegans
- The Immunosuppressant FK506 Uncovers a Positive Regulatory Cross-talk between the Hog1p and Gcn2p Pathways*
- The role of functional genomics in selecting disease targets for antibody‐based therapy
- Genomics and proteomics tools for compound mode-of-action studies in drug discovery.
- FK506 sensitizes mammalian cells to high osmolarity by modulating p38 MAP kinase activation
- Protein analysis based on molecular beacon probes and biofunctionalized nanoparticles
- Using C. elegans to screen for targets of ethanol and behavior-altering drugs
- Model systems in drug discovery: chemical genetics meets genomics.
- From genes to drugs: target validation in Caenorhabditis elegans.
- Combinatorial libraries and biological discovery.
- Targeting the CREB pathway for memory enhancers
- Génomique quantitative chez Caenorhabditis elegans : stratégies pour l’identification de nouvelles cibles thérapeutiques et de nouveaux mécanismes moléculaires chez l’homme
- Caenorhabditis elegans‐based in vivo screening of bioactives from marine sponge‐associated bacteria against Vibrio alginolyticus
- ARACHNE: a whole-genome shotgun assembler.
- Genome Sequencing and Genomic Technologies in Drug Discovery and Development
- Genomewide Association Study of Alcohol Dependence Identifies Risk Loci Altering Ethanol-response Behaviors in Model Organisms
- Cross-species molecular dissection across alcohol behavioral domains
- Potentials and Pitfalls of Cross-Translational Models of Cognitive Impairment
- Novel Epidermal Growth Factor Receptor Drug Platforms
- Optimistic Stratagems of Machine Based Deep Learning Employed with Automation in Psychiatry and Early Neurodevelopmental Disorders
Related papers
- From the sequence to cell modeling: comprehensive functional genomics in Escherichia coli.
- In vivo quantitative high-throughput screening for drug discovery and comparative toxicology
- Using a systems biological approach to develop novel therapeutics.
- Target identification and mechanism of action in chemical biology and drug discovery
- SiDMAP: a metabolomics approach to assess the effects of drug candidates on the dynamic properties of biochemical pathways
- Chemical genomics and emerging DNA technologies in the identification of drug mechanisms and drug targets.
- A survey of yeast genomic assays for drug and target discovery
- Prediction of higher order functional networks from genomic data.